Trigger 4: Hyperkalemia and Renal Failure Emergency * Identify the ECG changes and clinical presentation associated with severe hyperkalemia. * Formulate an acute management plan for severe hyperkalemia, including immediate cardiopulmonary stabilization

Reading File

Finding Sources

Searching Images

ECG changes in hyperkalemia peaked T waves widened QRS sine wave

Side-by-side comparison of two electrocardiogram (ECG) tracings (A and B) demonstrating the classic cardiotoxic evolution and subsequent resolution of severe hyperkalemia. Panel A (Pretreatment) displays several pathognomonic findings including prominent, tall, tented, or 'peaked' T-waves; significant flattening and widening of the P-waves; a prolonged PR interval; and a widened QRS complex with a 'sine-wave' appearance in certain leads. These features reflect impaired atrial and ventricular conduction and delayed repolarization associated with elevated serum potassium (e.g., 9.25 mEq/L). Panel B (Post-treatment) shows the results of medical intervention (such as calcium gluconate, insulin/glucose, and bicarbonate), characterized by the normalization of the ECG morphology. Key changes in Panel B include the return of distinct P-waves, narrowing of the QRS complex to normal duration, and a reduction in T-wave amplitude to a typical physiological morphology. The images are shown on standard ECG grid paper, facilitating the assessment of interval and complex durations.

Reading File

Searching PubMed

hyperkalemia AND management

Hyperkalemia and Renal Failure Emergency

1. ECG Changes and Clinical Presentation

Hyperkalemia (K+ > 5.5 mEq/L) causes increased membrane excitability followed by progressive conduction delay as levels rise. The Miller's Anesthesia staged progression is the clearest framework:

Serum K+	ECG Finding
5.5-6.5 mEq/L	Tall, peaked (tented), symmetric T-waves; shortened QT
6.5-7.5 mEq/L	Prolonged PR interval, flattened/widened P-wave, ST depression
>7.5 mEq/L	Widened QRS complex
>9.0 mEq/L	Sine-wave pattern, bradycardia, ventricular tachycardia/fibrillation, asystole/cardiac arrest

Miller's Anesthesia, p. 3806-3816 (block17)

Some patients also develop a Brugada-type pattern (pseudo-right bundle branch block with ST elevation in V1-V2) with severe hyperkalemia - Harrison's Principles of Internal Medicine, 22E.

ECG changes of severe hyperkalemia before and after treatment

Pretreatment: peaked T-waves, flattened/widened P-waves, prolonged PR, widened QRS with sine-wave morphology at K+ 9.25 mEq/L. Post-treatment: normalization after calcium gluconate, insulin/glucose, and bicarbonate.

Clinical presentation beyond the ECG:

Neuromuscular: ascending muscle weakness, paresthesias, hyporeflexia, and in severe cases flaccid paralysis (mimics Guillain-Barre)
Cardiac: palpitations, bradyarrhythmias, and risk of sudden cardiac arrest - often the presenting event in dialysis patients who miss sessions
Symptoms are frequently vague or absent until the cardiac toxicity is advanced, which is why any renal failure patient with unexplained weakness or bradycardia needs an immediate ECG and potassium level
Chronic hyperkalemia (e.g., CKD) is tolerated at higher levels than an acute rise, because the intracellular/extracellular K+ gradient has re-equilibrated - Miller's Anesthesia, p. 3816

2. Acute Management Plan

The sequence follows three goals: stabilize the myocardium, shift K+ intracellularly, then remove K+ from the body - with any ECG change or K+ >6.5 mEq/L treated as an emergency.

Step 0 - Stabilization/monitoring

Continuous cardiac monitor and 12-lead ECG immediately; IV access x2, telemetry bed/ICU-level care
Airway/breathing support as needed (severe hyperkalemia can cause respiratory muscle weakness); have advanced airway and defibrillator/ACLS drugs at bedside given risk of VF/pulseless arrest
Draw stat BMP, ionized calcium, magnesium, VBG, and send a repeat potassium to confirm (rule out hemolyzed sample) without delaying treatment if ECG changes are present

Step 1 - Membrane stabilization (antagonize cardiac toxicity) - give first if ECG changes present

IV calcium gluconate 10%, 10 mL (1 g) over 2-3 minutes, or calcium chloride 10% 5-10 mL if central access available (more caustic peripherally); repeat in 5-10 minutes if ECG changes persist
Calcium does not lower serum K+, it raises the threshold potential to directly counteract membrane excitability - Rosen's Emergency Medicine, p. 4589; Schwartz's Principles of Surgery, p. 4034
Caution: flush the line before/after if the patient is on digoxin (calcium can precipitate digoxin toxicity)

Step 2 - Shift potassium intracellularly

Regular insulin IV 10 units (or 0.1 units/kg) with dextrose (25-50 g D50, or D10 infusion if glucose is not already elevated) - drives K+ into cells via Na+/K+-ATPase; onset ~15-30 min, lasts 4-6 hours. Monitor glucose for delayed hypoglycemia.
Nebulized albuterol 10-20 mg (higher than the standard bronchodilator dose) - beta-2 agonism shifts K+ intracellularly, additive to insulin
Sodium bicarbonate (IV, ~1 mEq/kg or an ampule) - most useful when concurrent metabolic acidosis is present; less reliable as a standalone potassium-lowering agent in isolation but used adjunctively - Rosen's Emergency Medicine, p. 4589-4590; Miller's Anesthesia, p. 3135-3139

Step 3 - Remove potassium from the body

Loop diuretics (furosemide) if the patient has residual renal function and is not anuric, to promote kaliuresis
Potassium binders: newer agents (patiromer, sodium zirconium cyclosilicate) or older sodium polystyrene sulfonate (Kayexalate) - onset is hours, so these are adjuncts, not first-line for the acute crisis
Hemodialysis is the definitive treatment for renal failure patients, especially with K+ >6.5 mEq/L, anuria, refractory hyperkalemia, or ongoing ECG changes despite medical therapy - Miller's Anesthesia, p. 3816; Goldman-Cecil Medicine, p. 2887-2895

Ongoing care: recheck K+ and glucose within 1-2 hours, keep continuous ECG monitoring until normalization, identify and treat the underlying cause (medication review for ACEi/ARB/MRA/NSAIDs, assess for tissue breakdown/rhabdomyolysis/tumor lysis, arrange urgent nephrology consult for dialysis access if the patient is not already established on renal replacement therapy).

A recent 2025 systematic review and meta-analysis (Jessen et al., Resuscitation, PMID 39761907) evaluated pharmacological interventions for acute hyperkalemia treatment; it is worth checking for updated comparative efficacy data on insulin/albuterol dosing regimens, as this postdates the textbook chapters cited above and could refine relative drug sequencing recommendations.

This is a shared conversation. Sign in to Orris to start your own chat.